Form 4: Jazz Pharmaceuticals Director Heather McSharry Reports Stock Transactions

Director Heather McSharry reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares, including shares sold to cover tax obligations.

Summary

• On August 2, 2024, Heather McSharry, a director of Jazz Pharmaceuticals, acquired 3,731 ordinary shares as restricted stock units at a price of $0.0.
• These restricted stock units are part of the 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest fully on July 25, 2025, contingent upon continuous service and other conditions.
• Each unit represents a right to receive one ordinary share upon vesting.
• On August 6, 2024, McSharry disposed of 1,608 ordinary shares at a price of $111.35.
• The shares were sold to satisfy tax obligations related to the vesting of previously granted restricted stock units.
• Following these transactions, McSharry beneficially owns 18,901 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects routine stock transactions by a company director. There is no indication of positive or negative implications for the company's performance.

Future Outlook

The restricted stock units will vest on July 25, 2025, subject to the director's continuous service and other conditions.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common for publicly traded companies. It provides transparency into the trading activities of key personnel and their alignment with shareholder interests.

Comparison to Industry Standards

• Director stock transactions are a common occurrence in publicly traded companies like Jazz Pharmaceuticals.
• Similar transactions are regularly reported by directors and officers of comparable pharmaceutical companies such as Amgen, Gilead Sciences, and Biogen.
• These filings are mandated by the SEC to ensure transparency and prevent insider trading, aligning with standard corporate governance practices.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to director compensation and tax obligations.
• The disclosure provides transparency to shareholders regarding insider trading activities.

Key Dates